Rincon lithium project: US$2.5bn cost, 60,000tpa capacity, DLE technology and 2028 production timeline
Read More Pharma Industry News GSK to sell linerixibat rights to Alfasigma for up to $690m as rare liver disease drug nears FDA approval GSK and Alfasigma agree worldwide licence for linerixibat, a rare liver disease itch drug nearing FDA approval. Deal worth up to $690 million. Read more. byVenkateshMarch 9, 2026